Physician Views: Gauging early reaction to Sanofi, Regeneron's Dupixent for asthma

Sanofi and Regeneron Pharmaceuticals both unveiled their fourth-quarter earnings reports last week, highlighting the impressive growth trajectory of Dupixent in atopic dermatitis and also touting early success in the US asthma market, where it was approved last October.

FirstWord's latest Therapy Trends report (published last month; here for more details) provides expert opinion on the potential role of Dupixent in asthma and our latest Physician Views snap-poll - see below - seeks qualitative feedback from front-line prescribers.

Specifically we are asking US-based respirologists and pulmonologists…

In what type of patients have you prescribed Dupixent (dupilumab) most frequently to date?

Patients with moderate-to-severe asthma with eosinophilic phenotype

Patients with moderate-to-severe corticoid-dependent asthma, regardless of phenotype

-

Based on available data for Dupixent/your experience with the product, do you envisage significant adoption in patients with moderate (rather than severe) asthma over the next three years?

Yes

No

-

Dupixent is the only FDA-approved asthma biologic that offers patients self-administration at home. Has this/will this have a significant positive impact on your decision to prescribe Dupixent in favour of an alternative asthma biologic?

Yes

No

-

In comparison to less frequent dosing administration for other available biologic asthma therapies, do you think the need to administer Dupixent every two weeks will significantly limit its adoption?

[Note: please consider Dupixent is the only available biologic that can be self-administered at home]

Yes

No

-

Has the availability of Dupixent as a treatment for moderate-to-severe atopic dermatitis positively impacted your use of the product for asthma?

Yes

No

Results and related analysis will shortly be published for FirstWord Pharma PLUS subscribers to read, with the opportunity for non-FirstWord Pharma PLUS subscribers to purchase these findings. To be notified when poll results and analysis become available, please click here

As always, FirstWord would very much like to receive your feedback and suggestions.

Note: FirstWord Physician Views are a fast-turnaround service to conduct instant polls of up to five questions with guaranteed samples that include physicians from dozens of specialties in major markets. To conduct this poll with a different audience, or an entirely different poll, contact us at info@firstwordpharma.com.

Disclaimer: FirstWord follows market research best practices in conducting its Physician Views polls.  However, Physician Views results should be considered directional and clients should use their market research resources for statistical analysis and conclusions required with very high confidence levels.

To read more Physician Views articles, click here.